Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 1905Breast Neoplasms 1426Carcinoma, Non-Small-Cell Lung 1179Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 624Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Recurrence 374Lymphoma 374Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

capmatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × cMET Dysegulation Advanced Solid Tumors × Clear all
NCT02925104 2020-12-19

A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.

Novartis

Phase 1 Completed
36 enrolled
Other solid neoplasm

cMET Dysegulation Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡